Woburn, MA – According to filings with the U.S. Securities and Exchange Commission, Rgenta Therapeutics is raising $8,914,283.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Hualin Xi played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Rgenta Therapeutics
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Our lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases.

To learn more about Rgenta Therapeutics, visit http://www.rgentatx.com/

Contact:
Hualin Xi, Chief Executive Officer
781-608-3996
https://www.linkedin.com/in/simonxi/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved